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Abstract
Background: Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe
that sarcoma patients report a significantly worse experience than those with common cancers. Consequently,
Sarcoma UK conducted a national survey and these data were examined for age- and tumour-related differences in
patients’ experiences.
Methods: Patients were randomly selected from respondents to National Cancer Patient Experience Surveys
(n = 900). Differences between patient groups according to age (Adolescents and Young Adults [AYA] 18–39 years,
middle-aged 40–64 years, elderly 65 + years) and tumour type (soft-tissue [STS] vs. bone]) were analysed with t-tests or
chi-square tests.
Results: Survey response rate was 62% (n = 558; STS 75%, bone sarcoma 25%). Delay in diagnosis was
reported; 27% patients (n = 150) waited > 3 months and initial symptoms were incorrectly interpreted; AYA
STS patients were significantly more likely to be treated for another condition, or advised that their symptoms
were not serious, than older STS patients. Clinical trial participation was low (6%, n = 35). Symptom burden
was high, most commonly daytime fatigue (48%, n = 277) and pain (44%, n = 248). AYAs were significantly
more likely to report most side-effects and post-treatment concerns than older patients. Elderly patients were
more satisfied with the information and emotional support provided than younger patients, however were
significantly less likely to be referred to rehabilitation services.
Conclusions: This study identifies significant age-related differences in the sarcoma patient journey, which are
not only related to variation in tumour-types. These results provide rationale for adopting an age-specific
approach to the management of sarcoma patients in order to improve overall patient experience.
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Background
Sarcomas are rare and heterogeneous tumours of
mesenchymal origin, which account for approximately
1–2% of all adult solid malignancies [1]. In 2010, the
incidence of sarcomas in the United Kingdom (UK) was
3829 (3298 soft tissue, 531 bone) [2]. Sarcomas can
affect patients of any age and occur at almost any ana-
tomical site. Moreover, there are at least 70 histological
subtypes and therefore research is often limited by small
patient numbers [1].
Diagnosis is often delayed due to a lack of public
awareness of the symptoms of sarcoma, coupled with
limited experience among healthcare professionals [3].
Delay may allow the development of advanced disease,
which is not amenable to curative surgical resection [1].
In addition, many sarcomas demonstrate an aggressive
phenotype and around half of patients with high grade
tumours will eventually develop incurable disease [4, 5].
Despite improvements in the prognosis of many other
solid malignancies and certain sarcoma subtypes, the
five-year overall survival for soft tissue and bone sarco-
mas remains poor at around 50–60% [6].
Patients with sarcoma often have multiple complex
symptoms [7]. Burden of symptoms has been shown to
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have a negative impact on health-related quality of life
(HRQoL) in cancer patients [8, 9]. Patient reported
outcomes (PROs) including HRQoL are increasingly
recognised as key components of patient-centred care
and decision-making [10]. PROs reflect how patients feel
and function in relation to a disease, and its treatment,
without interpretation by others, including healthcare
professionals. PROs enable unique insight into the
effectiveness of care from the patient perspective, which
has particular relevance in an era of scarce resources and
rising treatment-costs [11] In addition, patient self-report
can itself improve symptom-management, communica-
tion, HRQoL and satisfaction with care [12, 13].
In view of the diversity of sarcoma histotypes across
the age-spectrum and specific developmental issues an
age-stratified approach to the overall management of
sarcomas seems appropriate from both the patients’ and
health care professionals’ perspective. Paediatric patients
most commonly develop rhabdomyosarcoma, whereas
adolescent and young adults (AYA) acquire synovial
sarcoma, Ewing sarcoma, osteosarcoma, desmoplastic
small round cell tumor, clear cell sarcoma, alveolar soft
part sarcoma, epithelioid sarcomas and malignant
peripheral nerve sheath tumours [14, 15]. Many of these
patients require intensive, multimodal treatment, includ-
ing chemotherapy, and may face potential long-term
side-effects [11]. AYA sarcoma patients also encounter
additional psychosocial challenges including changes in
body-image and relationships, as well as issues with
fertility, higher education, gaining employment and
financial difficulties [14, 15]. Adult sarcoma patients
most commonly develop undifferentiated sarcomas,
gastrointestinal stromal tumours, leiomyosarcomas and
liposarcomas requiring surgery, often radiotherapy and
on indication chemotherapy [11]. Unlike younger
patients, elderly patients often receive less aggressive
treatments possibly due to medical co-morbidities; a
factor associated with increased mortality [16]. It is also
acknowledged that elderly patients are disproportionally
underrepresented in clinical research trials [17]. Overall,
the treatment of sarcoma patients is often burdensome
due to bulky tumours, and at times may be challenging
due to anatomic locations such as the head and neck.
In 2014, the UK National Cancer Patient Experience
Survey (NCPES) identified that patients with rare can-
cers, including sarcomas, described a significantly poorer
experience of care than those with common cancers
[18]. They were less likely to feel that they were seen in
a timely manner, among other negative findings [18].
Following these results, Sarcoma UK (the largest
sarcoma-specific cancer charity in the UK) commis-
sioned and funded a national survey to gain additional
insight into the sarcoma patient journey. The Sarcoma
UK data were used in the present study to examine
age-related differences in the sarcoma patient journey.
Understanding the age-specific patient experience before,
during and after treatment is essential in order to develop
patient-centered services, which incorporate biomedical
and psychosocial needs with existing clinical knowledge.
Methods
Patients
This study was a cross-sectional survey of adult sarcoma
patients (aged 18 years and older) in England. Patients
were identified from respondents to the NCPES 2012–
14, who indicated willingness to be contacted for future
questionnaires. The NCPES is an annual survey commis-
sioned by the National Health Service in England. The
NCPES is sent to all patients with cancer who have been
discharged after an inpatient or day-case admission (over
a specified three-month period) from one of the acute
and specialist NHS trusts in England that provide adult
cancer services. Public Health England have reported
high concurrence between NCPES respondents and a
newly diagnosed cancer population-based dataset, with
regard to age, sex, ethnicity and deprivation, however
NCPES has slight over-representation of patients aged
51–75 years and of white ethnicity: reflecting known bias
in survey responders [19]. Patients with tumour types
which are more likely to be treated as an outpatient are
under-represented [19]. The NCPES does not collect
data on date of diagnosis or stage of disease. The flow
diagram (Fig. 1) demonstrates how the patient sample
was selected for the Sarcoma UK patient survey.
Deceased patients, duplicated patients or those without
a validated address were identified and excluded from
the study. Preference was given to those patients who
participated in the most recent NCPES: 2014 (n = 452),
2013 (n = 343), 2012 (n = 105). Patients were approached
independent of their stage of disease, which was not
identified for this survey. The final sample size was 900.
Ethical approval was not required for this secondary
study as the NCPES is underpinned by section 251
approval from the Secretary of State to cover every
hospital in England providing adult cancer services.
Annual approval for NCPES is reviewed by the The
Ethics and Confidentiality Committee of the National
Information Governance Board. Patient consent was
implicit through completion of the Sarcoma UK question-
naire. Patients were advised that they could withdraw the
information that they had provided in the questionnaire
upon request, up to the point at which personal details
were removed and data was analysed.
Materials
Questionnaires were designed by Quality Health, an
independent agency approved by the Care Quality
Commission specialising in national patient surveys, in
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conjunction with Sarcoma UK, patient advocates and
sarcoma clinicians. The questionnaire aimed to provide
a comprehensive overview of the sarcoma patient experi-
ence and focused on three areas of the patient journey:
diagnosis, treatment and post-treatment. Questionnaires
were dispatched to patients by post and two reminders
sent to non-respondents as necessary within the
12-week period. Fieldwork was undertaken between
January–March 2015. Questionnaires were returned by
post to Quality Health for analysis.
Statistical analysis
Patients who completed the questionnaire were grouped
by tumour-type (STS or bone sarcoma) and age [(AYA;
18–39 years), middle-aged (40–64 years) and elderly (65
+ years)]. Certain questions were not applicable to all
participants and therefore missing data for these ques-
tions was assumed to be ‘missing not at random’ (e.g.
question 28 ‘If you had a bone sarcoma were you given
information from the Bone Cancer Research trust?’ For
other questions only available data were analysed.
Missing items were assumed to be missing completely at
random. Descriptive statistics were used to describe the
study sample. For continuous variables, mean values and
standard deviations are presented. Categorical variables
are represented by numbers and percentages and
chi-square tests were conducted to detect differences
between tumour-type and age groups. Adjusted residual
values were calculated to identify significant differences
with a significance level of α = 0.05. All data analysis was
performed using IBM SPSS 22.0.
Results
Patient characteristics (Table 1)
Of the 900 patients invited, 558 patients completed the
survey (response rate 62%): 418 STS (75%) and 140 bone
sarcoma (25%). Response rates for STS patients and
bone sarcoma patients were equal (62%). Mean age of
respondents was 64.1 years (SD 14, range 18–96). There
were 46 AYA (bone sarcoma, n = 23, STS n = 23), 285
middle-aged (bone sarcoma, n = 78, STS n = 207) and
227 elderly patients (bone sarcoma n = 39, STS n = 188).
Response rate varied according to age: AYA 60%,
middle-aged 82% and elderly 48%. Gender distribution
was almost equal (male n = 274, 49%, female n = 284,
51%). ‘Lower limb’ was the most common primary site
of disease in both STS and bone sarcoma patients (total
n = 177, 32%). The total number of patients treated with
surgery was 502 (90%), radiotherapy (n = 246 patients,
44.1%) and chemotherapy (n = 201, 36.0%). AYA patients
(STS and bone sarcoma) were significantly more likely
to have been treated with chemotherapy than
middle-aged and elderly patients (80% AYA vs. 40% mid-
dle-aged vs. 22% elderly: p < 0.001). Most patients had
three-monthly (n = 232, 45.4%) or 6 monthly (n = 109,
21.3%) follow-up.
Diagnosis
The most common presenting symptom overall was a
‘painless lump’ (n = 229, 41%). Elderly STS patients were
more likely to present with a painless lump than AYA
and middle-aged patients (p = 0.038). In contrast, bone
pain was most common in bone sarcoma patients (n =
44, 31%) and was a more common presenting symptom
in AYA bone sarcoma patients than other bone sarcoma
age groups (p = 0.011).
Almost half of patients (n = 251, 48%) presented to a
medical professional within 4 weeks of first developing
symptoms, however, more than a quarter waited > 3 months
(n = 150, 27%) and one in ten > 1 year (n = 54, 10%) before
seeking medical advice. Presentation was more likely to be
delayed in bone sarcoma than STS patients (p = 0.047).
Fig. 1 Participant selection process
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There were no age-related differences in time to
presentation.
Most patients sought advice from their General Prac-
titioner (GP) (n = 447, 80%) about their symptoms.
Within this cohort of patients, GPs referred 324 pa-
tients (72%) either for further investigations, to a hos-
pital specialist or immediately admitted to hospital. An
incorrect interpretation of symptoms and subsequent
advice was given to 123 patients (28%). This included
those treated for another condition (n = 42, 8.6%), those
who were told that their symptoms were not serious
but to return if they persisted (n = 41, 8.4%) and those
who were not advised to return if symptoms persisted
(n = 40, 8.1%). Elderly bone sarcoma patients (n = 21,
87.5%) were significantly more likely to be referred for
investigation than younger patients while AYA bone
sarcoma patients were more frequently treated for
another condition or advised their symptoms were not
serious (n = 10, 50%; p = 0.021). Elderly STS patients
(n = 123, 78.3%) were also more likely to be referred
and AYA STS patients more likely to be treated for
another condition or advised that their symptoms
were not serious (n = 8, 53.3%; p = 0.001).
Approximately one fifth of patients presented to the
Emergency Department (ED) (n = 121, 22%). Similarly, of
those seen in the ED, 91 patients (75%) were referred for
further investigation and 30 patients (25%) were treated
for another condition or advised their symptoms were not
serious. No significant age-related differences were identi-
fied in bone sarcoma patients. However, in STS patients,
the elderly were more likely to be further investigated than
younger patients and AYA and middle-aged patients were
more commonly treated for another condition or told
their symptoms were not serious (p = 0.02).
Table 1 Patient Demographics




















Mean(SD) 64.1 (15.5) 57 (18.0) 66.2 (14.0) 26.4 (6.9) 57.4 (8.7) 77 (5.0) 31.1 (5.6) 59.7 (8.3) 77.6 (5.5)
Gender
Male 274 (49.1%) 78 (55.7%) 196 (46.9%) 15 (65.2%) 40 (51.3%) 23 (59.0%) 8 (34.8%) 91 (44.0%) 97 (51.6%)
Female 284 (50.9%) 62 (44.3%) 222 (53.1%) 8 (34.8%) 38 (48.7%) 16 (41.0%) 15 (65.2%) 116 (56.0%) 91 (48.4%)
Site of Disease
Head/neck 70 (12.5% 44 (31.4%) 26 (6.2%) 1 (4.3%) 24 (30.8%) 19 (48.7%) 2 (8.7%) 9 (4.3%) 15 (8.0%)
Thorax 32 (5.7%) 6 (4.3%) 26 (6.2%) 1 (4.3%) 3 (3.8%) 2 (5.1%) 1 (4.3%) 14 (6.8%) 11 (5.9%)
Abdomen 129 (23.1%) n/a 129 (30.9%) n/a n/a n/a 6 (26.1%) 63 (30.4%) 60 (31.9%)
Pelvis 46 (8.2%) 21 (15.0%) 25 (6.0%) 5 (21.7%) 11 (14.1%) 5 (12.8%) 1 (4.3%) 15 (7.2%) 9 (4.8%)
Upper limb 68 (12.2%) 15 (10.7%) 53 (12.7%) 3 (13.0%) 8 (10.3%) 4 (10.3%) 3 (13.0%) 22 (10.6%) 28 (14.9%)
Lower limb 177 (31.7%) 40 (28.6%) 137 (32.8%) 11 (47.8%) 21 (26.9%) 8 (20.5%) 9 (39.1%) 70 (33.8%) 58 (30.9%)
Vertebral column 6 (1.1%) 6 (4.3%) n/a 1 (4.3%) 5 (6.4%) 0 (0.0%) n/a n/a n/a
Skin 9 (1.6%) n/a 9 (2.2%) n/a n/a n/a 1 (4.3%) 6 (2.9%) 2 (1.1%)
Unspecified 21 (3.8%) 8 (5.7%) 13 (3.1%) 1 (4.3%) 6 (7.7%) 1 (2.6%) 0 (0.0%) 8 (3.9%)
Treatments Received
Surgery 502 (90.0%) 129 (92.1%) 374 (89.5%) 18 (78.3%) 75 (96.2%) 36 (92.3%) 19 (82.6%) 186 (90.0%) 169 (90%)
Radiotherapy 246 (44.1%) 58 (41.4%) 188 (45.0%) 13 (56.5%) 32 (41.0%) 13 (33.3%) 16 (69.6%) 95 (45.9%) 77 (41.0%)
Chemotherapy 201 (36.0%) 55 (39.3%) 146 (34.9%) 20 (87.0%) 33 (42.3%) 2 (5.1%) 17 (73.9%) 81 (39.1%) 48 (25.5%)
Other 27 (4.8%) 10 (7.1%) 17 (4.1%) 2 (8.7%) 5 (6.4%) 3 (7.7%) 0 (0.0%) 11 (5.3%) 6 (3.2%)
Follow-up
< 3 monthly 89 (17.4%) 37 (28.2%) 52 (13.7%) 7 (30.4%) 17 (23.9%) 13 (35.1%) 3 (13.4%) 30 (15.8%) 19 (11.2%)
3 monthly 232 (45.4%) 49 (37.4%) 183 (48.2%) 9 (39.1%) 32 (45.1%) 8 (21.6%) 12 (57.1%) 94 (49.5%) 77 (45.6%)
> 3–6 monthly 128 (25.0%) 34 (26.0%) 94 (24.7%) 5 (21.7%) 18 (25.4%) 11 (29.7%) 3 (14.3%) 41 (21.6%) 50 (29.6%)
Annual 23 (4.5%) 6 (4.6%) 17 (4.5%) 2 (8.7%) 1 (1.4%) 3 (0.0%) 0 (0.0%) 11 (5.8%) 6 (3.6%)
Never 12 (2.3%) 1 (0.8%) 11 (2.9%) 0 (0%) 1 (1.4%) 0 (0%) 1 (4.8%) 3 (1.6%) 7 (4.1%)
Variable 27 (5.3%) 4 (3.1%) 23 (6.1%) 0 (0%) 2 (2.8%) 2 (5.4%) 2 (9.5%) 11 (5.8%) 10 (5.9%)
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Overall, 104 patients (20%) were told that they may
have a sarcoma when first presenting with symptoms.
This was significantly more likely in elderly bone
sarcoma patients (n = 15, 45.5%) compared to AYA (n =
2, 9.1%) and middle-aged (n = 10, 14.3%) bone sarcoma
patients (p = 0.003), and in elderly STS patients (n = 49,
27.7%) compared to AYA (n = 4, 17.4%) and middle-aged
(n = 24, 12.1%) STS patients (p = 0.001). For further de-
tails, see Additional file 1.
Treatment
Most patients (n = 475, 87%) reported that they were
treated by a specialist sarcoma team and had a clinical
nurse specialist (n = 407, 76%). Patients were often
treated at more than one hospital (n = 368, 66%). Most
patients “did not mind” travelling for surgical treatment
(n = 451, 89%) and almost half (n = 260, 49%) journeyed
at least 20 miles for an operation. Patients who were
treated with chemotherapy and/or radiotherapy in
addition to surgery often had to travel to a different
hospital for this treatment (n = 209, 62%). AYA bone
sarcoma patients (n = 17, 85%) were significantly more
likely to attend another hospital for these additional treat-
ments (p = < 0.001) and to be treated at more than three
hospitals (p = 0.033) than older bone sarcoma patients.
One third of patients (n = 158, 30%) were offered
participation in a clinical trial, of whom a small number
participated (n = 35, 22%). Consequently, 6% of all
participants were involved in a clinical trial. AYA bone
sarcoma patients were more likely to be offered (n = 13,
57%; p = 0.013) and to participate (n = 12, 52%; p =
0.004) in a clinical trial compared to middle-aged and
elderly bone sarcoma patients. There were no significant
age-related differences in clinical trial accrual among the
STS patients (Additional file 2).
Most patients (n = 472, 87%) felt that they were given
sufficient information to make informed decisions about
their care. Almost half of patients were provided with a
complete written treatment plan (n = 237, 48%). Elderly
patients (bone sarcoma n = 39, STS n = 188) were more
likely to report satisfaction with the information given
than AYA and middle-aged patients (bone sarcoma
p = < 0.001, STS p = 0.049).
Most patients (n = 441, 81%,) were given adequate
emotional support from hospital staff, however 40
patients (7%) would have preferred more support and 64
patients (12%) did not feel that this was necessary.
Elderly bone sarcoma patients (n = 33, 85%; p = 0.006)
and elderly STS (n = 115, 64%; p = 0.003) were more
likely to report sufficient emotional support than AYA
(n = 12, 52%) and middle-aged (n = 39, 51%) bone
sarcoma patients, and AYA (n = 9, 41%) and middle-aged
(n = 100, 49%) STS patients (Additional file 2).
The most common symptoms and side effects of
treatment were daytime fatigue (n = 277, 47.7%) and
pain (n = 248, 44.4%). Pain was the symptom with the
greatest impact on patients’ lives (n = 92, 25%). AYA bone
sarcoma and STS patients were significantly more likely to
recall side effects of treatment than middle-aged and
elderly patients. Middle-aged patients were also more
likely to report side effects than elderly patients in STS
and bone sarcoma groups (Fig. 2a and b).
Support and follow-up
Most patients felt that follow-up information was very
clear (n = 428, 85%) and knew how to contact the
sarcoma team for information (n = 482, 89%). Patients
were most likely to be referred to physiotherapy after
treatment (n = 184, 33%). Referral was significantly more
likely in AYA and middle-aged bone sarcoma patients
than elderly bone sarcoma patients (p = 0.03). Similarly,
AYA STS patients were more commonly referred for
physiotherapy than older patients (p = 0.03). Rehabilita-
tion services were helpful for 176 patients (48%),
however 105 patients (29%) found minimal benefit and
49 patients (13%) not useful at all. No age-specific
differences were observed.
One quarter of patients (n = 133, 24%) were aware of
Sarcoma UK and given a Sarcoma UK toolkit (n = 104,
19%). A minority of patients were told about generic (n =
134, 28%) or sarcoma-specific (n = 92, 18%) local support
groups. Patients used online national UK charity websites
including Macmillan (n = 231, 48%) and Cancer Research
UK (CRUK) (n = 108, 22%). AYA and middle-aged bone
sarcoma patients were significantly more likely to use
Macmillan (p < 0.001) and CRUK (p = 0.003) websites than
elderly bone sarcoma patients. AYA STS patients were
more likely to use Macmillan and Sarcoma UK than older
patients (p < 0.001). Middle-aged bone sarcoma patients
were more likely to use Sarcoma UK than elderly (p =
0.032). See Additional file 3.
Fear of cancer recurrence was the most common post-
treatment concern (n = 398, 72%). Many post-treatment
concerns were more common in AYA (bone sarcoma
and STS patients) compared with middle-aged and eld-
erly patients. Middle-aged patients also reported more
worries than elderly patients (Fig. 3: Post-treatment con-
cerns). Worry about ‘cancer coming back’ was signifi-
cantly more common among AYA and middle-aged
patients compared with elderly patients (AYA 80%,
middle-aged 76%, elderly 64%, p = 0.005). AYA and
middle-aged patients were more likely to report worries
about ‘coping with side effects of treatment’ (AYA 37%,
middle-aged 30%, elderly 18%, p = 0.001). AYA were the
most likely group to have worries about coping with
disability caused by surgery (AYA 48%, middle-aged
32%, elderly 20%, p < 0.001). Worries about family and
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friends were most commonly reported by AYA and
middle-aged patients (AYA 46%, middle-aged 37%,
elderly 17%, p < 0.001). Worries about ‘loss of control of
my life’, the ‘possibility of dying’ and financial concerns
were also more common in AYA and middle-aged
patients compared with elderly patients. There were no
other statistically significant differences in worries
between age-groups.
Discussion
To our knowledge, this is the first large-scale study of
the sarcoma patient journey from the patient perspec-
tive. In accordance with current UK guidelines [20, 21],
the majority of patients were treated under the care of a
specialist sarcoma team and received support from a
clinical nurse specialist.
Diagnostic trajectory
Delay in patient presentation was observed in the
diagnostic trajectory. We found that 27% of patients
presented more than 3 months after first noting
symptoms and 10% of patients waited more than 1
year before seeking advice for their symptoms. Patient
age was not associated with time to presentation. Our
findings are consistent with a previous UK survey of


























AYA STS (n=23) Middle-age STS (n=207) Elderly STS (n=188)
a
b
Fig. 2 a. Percentages of bone sarcoma patients with symptoms or side-effects according to the different age groups. Heading – Bone Sarcoma
Legends: • AYA Bone (n = 23), •Middle-age Bone (n = 78), •Elderly Bone (n = 39). b. Percentage of soft tissue sarcoma patients with symptoms or
side-effects according to the different age groups. Heading – Soft Tissue Sarcoma. Legends: •AYA STS (n = 23), •Middle-age STS (n = 207),
•Elderly (n = 188)
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sarcoma patients (n = 127) delayed > 3 months from
symptom-onset to first presentation, and was not
associated with patient-age [22]. Patient-delay in other
malignancies varied from 8.5% (breast) to 47.8%
(prostate) [22].
Almost three-quarters of participants in this study
were referred for further evaluation by their GP or ED
doctor, after seeking advice for their symptoms.
Approximately one quarter of patients who presented to
a medical practitioner with symptoms reported that they
were treated for another condition or advised that their
symptoms were not serious. AYA patients were more
likely to be treated for another condition or advised that
their symptoms were not serious, whereas elderly
patients were more likely to be referred for further
evaluation. Previous data has also demonstrated that
AYA cancer patients are significantly more likely to have
seen their GP ≥3 times before referral than older
patients [23]. This may be due to low clinical suspicion
of cancer in this age group and may lead to delay in
diagnosis. Overall, given the low incidence of sarcomas,
professionals may only encounter one case in their
career [24]. In addition, only approximately one in 100
soft tissue lumps are malignant, leading to low clinical
suspicion [24]. Previous research has shown that patients
with sarcomas are more likely to have seen their GP > 2
times before referral to hospital (41%) compared to
others malignancies, such as breast 8% and skin 10%
cancer [18]. They are also less likely to be referred by
the ‘Two Week Wait’ (TWW) system, which ensures
that patients with suspected cancer are seen within 2
weeks (10% bone sarcoma, 12% STS vs. 25% all cancers)
[25]. Patients with central nervous system (1%) and
pancreatic (11%) malignancies are also less commonly
diagnosed via the TWW route [26].
We found that one fifth of patients presented with first
symptoms to the ED but this was not associated with
patient age. The high number of emergency presenta-
tions is particularly concerning as this is associated with
more advanced disease and significantly lower survival
rates in patients with other cancers, even when adjusted
for stage of disease at diagnosis [25–27]. A previous UK
study demonstrated that 18.6% of sarcomas and 23% of
all cancers were diagnosed through ‘emergency presenta-
tion’ between 2006 and 2008 [25]. This study also found
that bone sarcoma patients aged < 10 or > 80 years, and
STS patients aged < 19 or > 80, were more likely to
present to ED [25]. Although we did not find this associ-
ation, our survey did not include paediatric patients and
our sample size was considerably smaller (558 vs. 8956
patients) [25]. Others have also found that emergency
presentation is more common in elderly cancer patients,
which may itself contribute to increased mortality [26].
Emergency presentation may be unavoidable due to
tumour-related factors; however research indicates that
many patients have had consultations within 12 months
of diagnosis. This indicates that there may be opportun-
ities to reduce the number of emergency cancer presen-
tations [27].
UK cancer survival figures are significantly lower than
most European countries, a finding that has been attrib-
uted to late stage diagnosis [28]. In the UK a relatively
high number of patients present to the ED before



















Fig. 3 Percentage of sarcoma patients with post-treatment concerns according to age groups. Heading – Post-treatment concerns Legends:
•AYA, •Middle-aged, •Elderly
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Medicine (RCEM) and The Patients Association
reported that patients often attended ED because they
felt unable to access timely help elsewhere and perceived
that they would be able to access immediate diagnostic
investigations and specialist opinion [29]. This included
patients with symptoms which had been present for days
or even weeks, who were offered a GP appointment the
same day however still chose to attend ED instead. For
lung cancer this has been exemplified by a study of eight
European countries. In this study an emergency route to
lung cancer diagnosis was most likely in the UK and
Portugal, and least common in The Netherlands [30].
Disparities in routes to diagnosis may influence
outcomes for UK cancer patients compared with their
European counterparts.
Treatment
In accordance with findings of the NCPES, less than one
third of patients (30%) were offered the opportunity to
participate in a clinical trial [18]. AYA bone sarcoma
patients were significantly more likely to be involved in
a clinical trial than all other groups. These findings
reflect the availability of clinical trials enrolling patients
at the time of the survey, which included large inter-
national trials for bone sarcoma and few trials for first
presentation of STS. It is internationally acknowledged
that there are significant age inequalities in clinical trial
accrual among cancer patients. Previous studies have
demonstrated that AYA cancer patients overall are less
commonly enrolled in clinical trials than paediatric and
adult patients [31]. Lack of involvement in research trials
is believed to be responsible for slower progress in
survival outcomes for AYA cancer patients [31, 32].
Older patients are also often disproportionally underrep-
resented in clinical research trials despite an increasing
incidence of sarcomas with advancing age [33].
Comparable with other cancers, many sarcoma patients
reported a high burden of symptoms and side-effects of
treatment, most commonly daytime fatigue [34]. Notably,
almost all symptoms and side effects of treatment
occurred with increased frequency among AYA patients,
however AYAs were significantly more likely to have been
treated with chemotherapy than older patients. A large
study of patients with advanced cancer also found that
increasing age was associated with lower reporting of
symptoms, however this association has not been repli-
cated in all studies [35]. Older patients may report less
symptoms due to physiological changes associated with
ageing, lower levels of physical activity, less work-related
and social activities compared with younger patients, and
possibly a more tolerant attitude toward illness [35, 36].
Elderly patients were significantly more satisfied with the
information and emotional support provided than
younger patients. This is consistent with research
demonstrating a paternalistic attitude of older patients,
who report higher levels of satisfaction with care, which
correlates with enhanced QoL than younger patients [37].
Supportive care
The majority of post-treatment concerns were most
common in AYA patients. AYAs who are diagnosed with
cancer are suddenly faced with existential questions
during a critical phase in their life [32]. While their
siblings and peers are progressing forward with educa-
tion and relationships, their own journey is suddenly
and unexpectedly altered [32]. The AYA-HOPE study
also found a high prevalence of unmet psychosocial
needs and reduced HRQoL in AYA cancer survivors
compared with an age and sex matched population [38].
Studies of multiple myeloma and lymphoma patients
have also demonstrated that the elderly are less likely to
experience deterioration in HRQoL, compared with a
normative population, than younger patients [39, 40].
Clinical implications
Despite the growing body of evidence that early diagno-
sis improves survival in many common cancers, the
impact in sarcomas has not been clearly established and
may be limited to certain subtypes [24, 41–43]. The
intrinsically aggressive disease biology of some sarcomas
may override any potential influence of delay on survival
outcomes [32]. Nonetheless, it would seem rational to
strive toward early diagnosis for those in whom early
treatment may improve outcome. Additionally, delayed
diagnosis can cause psychological distress and may lead
to tumour growth with reduced potential for curative
localised surgery. Public awareness campaigns for com-
mon cancers are well established. Strategies to improve
awareness of ‘alarm’ symptoms of sarcomas, such as a
lump larger than a ‘golf ball’, increasing size > 5 cm, deep
to the fascia, or persistent deep bone pain have recently
been introduced to public awareness programs [44, 45].
Medical professionals must also be aware that sarcomas
can affect AYAs and thus avoid delayed referral in this
age group. Unlike care for paediatric patients, which is
often centralized and protocol-driven, AYAs often fall
between services for paediatric and adult patients [46].
AYAs also encounter unique developmental challenges
and it is unquestionable that an age-specific approach is
required for these patients [47].
The high symptom-burden must be addressed,
particularly for AYAs and those who have received
intensive treatment. Early integration of specialist
symptom control teams can improve HRQoL, satisfac-
tion with care and reduce rates of depression in cancer
patients [48]. In addition, this intervention has demon-
strated a survival benefit in metastatic non-small-cell
lung cancer patients [49]. Pain screening and early
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referral to a pain treatment protocol has been successful
in head and neck cancer patients [50]. Based on results
from this survey, it is probable that a multidisciplinary,
symptom-oriented approach would be also beneficial for
the sarcoma population.
Elderly patients with bone sarcoma were uncommonly
involved in research and overall were less likely to be
referred to rehabilitation services. Although physical and
cognitive problems may require optimisation, it is vital
that chronological age is not a barrier to involvement in
clinical research, nor interventions which may improve
HRQoL [17].
Limitations
Limitations of this study include the lack of patient
details, such as race or ethnicity, geographic location of
participants, disease stage and interval from diagnosis to
participation in the study. Patients with localized disease
encounter very different challenges to those with
advanced disease, and consequently, the lack of data re-
garding disease stage means that it is not clear whether
this sample is truly representative of the general sarcoma
population. Additionally, the NCPES only includes
patients who were discharged from hospital following a
day-case or inpatient admission. This means that
patients with certain sarcoma subtypes, such as endo-
metrial stromal sarcoma or gastro-intestinal stromal
tumour (GIST), who are more commonly treated as an
outpatient with oral therapy would not have been invited
to participate in the NCPES and thus are likely to be
under-represented in the Sarcoma UK patient survey.
Age-based comparisons were limited due to the small
sample size of the group of AYA patients (n = 46),
however statistical analysis was used to identify true
differences across the age groups. The response rate was
higher in middle-aged patients than AYA or elderly
patients: reflecting a known bias in survey respondents.
Survivorship bias was introduced by selection of patients
who participated in NCPES from 2012 to 2014, which
means they will have survived at least 1 year since diag-
nosis. These patients are likely to have a better prognosis
than an unselected population of sarcoma patients. This
study did not use internationally a validated question-
naire, however was designed by sarcoma patients and
experts in a similar format to previous NCPES in order
that patients were familiar with the terminology used.
The meaning of a ‘clinical trial’ was open to interpretation
by the patient and therefore participation rates should be
interpreted with caution. As with all patient surveys, it is
possible that recall bias had an influence on our results.
The perspective of the healthcare professional (e.g. GP)
was not surveyed and therefore all results are based on
the patient’s perception of their individual experience.
Conclusions
In this study, describing the largest sarcoma patient
survey to date, we identified significant age-related
differences in the sarcoma patient journey. AYA pa-
tients appear more vulnerable to incorrect diagnosis, a
high burden of treatment related side effects and
post-treatment psychological concerns. Elderly patients
reported less trial participation and were less likely to
be referred to rehabilitation services. Overall, the bur-
den of disease was felt high. Despite the general focus
of physicians and researchers on the anatomic and
histological heterogeneity of sarcomas, from a patient
perspective attention should also be paid to the differ-
ences in age-related aspects of diagnosis, treatment,
trial access and survivorship. The findings suggest a ra-
tionale for integrating an age-stratified approach to the
general management of sarcoma patients.
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